Olivier Bruyère, WCO IOF-ESCEO 2022: the SarQoL Questionnaire in Sarcopenia

Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]

The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) to discuss the aims, design and findings from his interim analysis of the […]

Hereditary angioedema with C1-inhibitor deficiency (HAE-C1-INH) is a rare disease resulting in unpredictable attacks of swelling under the skin. touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) around the health burden of HAE-C1-INH and the unmet needs in its treatment. The abstract ‘Lanadelumab Treatment Patterns Among Patients With HAE-C1-INH: Interim […]